Mechanisms of Risk for Sulfonamide Hypersensitivity

Request Access

Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity.

N. Shear, S P Spielberg, D. Grant, et al.. (1986). Annals of internal medicine. Cited 358 times. https://doi.org/10.7326/0003-4819-105-2-179

Metabolic predisposition to cutaneous adverse drug reactions. Role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants.

P. Wolkenstein, D. Charue, P. Laurent, et al.. (1995). Archives of dermatology. Cited 150 times. https://doi.org/10.1001/ARCHDERM.1995.01690170046006

Adverse reactions to sulphonamide and sulphonamide-trimethoprim antimicrobials: clinical syndromes and pathogenesis.

A. Cribb, B. Lee, L. Trepanier, et al.. (1996). Adverse drug reactions and toxicological reviews. Cited 144 times.

Clinical study of cutaneous drug eruptions in 200 patients.

R. Patel, Y. Marfatia. (2008). Indian journal of dermatology, venereology and leprology. Cited 134 times. https://doi.org/10.4103/0378-6323.38431

Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype.

E. Özkaya‐Bayazit, U. Akar. (2001). Journal of the American Academy of Dermatology. Cited 78 times. https://doi.org/10.1067/MJD.2001.117854

A novel lymphocyte toxicity assay to assess drug hypersensitivity syndromes.

M. Neuman, I. Malkiewicz, N. Shear. (2000). Clinical biochemistry. Cited 73 times. https://doi.org/10.1016/S0009-9120(00)00146-6

Fixed drug eruptions in children.

J. Morelli, Y. Tay, Maureenn Rogers, et al.. (1999). The Journal of pediatrics. Cited 57 times. https://doi.org/10.1016/S0022-3476(99)70472-5

The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.

Helen J. Gill, J. Tjia, N. Kitteringham, et al.. (1999). Pharmacogenetics. Cited 52 times. https://doi.org/10.1097/00008571-199902000-00007

Glutathione S-transferase polymorphisms in patients with drug eruption

N. Ateş, U. Tursen, L. Tamer, et al.. (2004). Archives of Dermatological Research. Cited 26 times. https://doi.org/10.1007/s00403-003-0446-z

Evaluation of polymorphisms in the sulfonamide detoxification genes NAT2, CYB5A, and CYB5R3 in patients with sulfonamide hypersensitivity

J. Sacco, Mahmoud Abouraya, A. Motsinger-Reif, et al.. (2012). Pharmacogenetics and Genomics. Cited 24 times. https://doi.org/10.1097/FPC.0b013e328357a735

Genome-Wide Association Study in Immunocompetent Patients with Delayed Hypersensitivity to Sulfonamide Antimicrobials

J. M. Reinhart, A. Motsinger-Reif, A. Dickey, et al.. (2016). PLoS ONE. Cited 16 times. https://doi.org/10.1371/journal.pone.0156000

[Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: retrospective study of 89 cases].

B. Saka, K. Kombaté, A. Mouhari-toure, et al.. (2010). Medecine tropicale : revue du Corps de sante colonial. Cited 12 times.

Toxic epidermal necrolysis-case report and review of the literature.

J. E. Ortíz, M. Horn, H. D. Peterson. (1982). Annals of plastic surgery. Cited 10 times. https://doi.org/10.1097/00000637-198209000-00011

Familial tendency in hypersensitivity reactions to co-trimoxazole.

J. Mohanasundaram, S. Rajaram, S. Mohanasundaram. (1998). Journal of the Indian Medical Association. Cited 5 times.
NCPI Dataset Catalog
Feedback & Support
v0.9.0-d9e5747